Comparing Revo-i and da Vinci in Retzius-Sparing Robot-Assisted Radical Prostatectomy: A Preliminary Propensity Score Analysis of Outcomes - Beyond the Abstract

Urologic surgery has been at the forefront of robotic surgery development. Some may argue that robotic integration may soon take the place of the surgeon in the operating room. The authors of this article believe the contrary to be true. It is the onus of the surgeon, to continuously establish standards that are most efficient, least invasive, with an accessible cost for the greatest number of individuals. In this vein, newer robots have followed da Vinci’s lead, in an effort to level the commercial playing field and bring down the cost of care.


Our study explores one such robot – the Revo-i (Meerecompany, Seongnam, Republic of Korea). Although from a research point of view, a 33-patient sample is a small number, this is the largest study done on this novel robotic system, and one of the biggest preliminary studies for a new robotic system. We explore short-term oncologic outcomes in this study and expect longer-term outcomes in studies to come. A matched prostate cancer cohort serves as the matched control; we have published along with it a supplementary table, which accompanies the full text of the article, in which the Revo-i cohort is compared to an 1121 single surgeon Retzius-sparing robot prostatectomy cohort.

Written by: Sylvia Alip, MD, University of the Philippines-Philippine General Hospital Department of Surgery, Urology, Manila, Philippines

Read the Abstract
email news signup